Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-10-10
2006-10-10
Andres, Janet L. (Department: 1646)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S173300, C435S235100, C435S325000, C435S320100, C536S063000
Reexamination Certificate
active
07119190
ABSTRACT:
The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor and to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
REFERENCES:
patent: 5514578 (1996-05-01), Hogness et al.
patent: 5532157 (1996-07-01), Fink
patent: 5573944 (1996-11-01), Kirschner et al.
patent: 5639616 (1997-06-01), Liao et al.
patent: 5750353 (1998-05-01), Kopin et al.
patent: 5861309 (1999-01-01), Bard et al.
patent: 5891720 (1999-04-01), Moore et al.
patent: 5955308 (1999-09-01), Bergsma et al.
patent: 6159705 (2000-12-01), Truehart et al.
patent: 6235481 (2001-05-01), Horikawa et al.
patent: 2135253 (1996-08-01), None
patent: 0 612 845 (1994-08-01), None
patent: 0 878 542 (1998-11-01), None
patent: 0 892 051 (1999-01-01), None
patent: 1 090 989 (2001-04-01), None
patent: 1 094 076 (2001-04-01), None
patent: 11-98988 (1999-09-01), None
patent: WO 96/05302 (1996-02-01), None
patent: WO 97/11159 (1996-09-01), None
patent: WO 97/21731 (1997-06-01), None
patent: WO 97/21731 (1997-06-01), None
patent: WO 98/00552 (1998-01-01), None
patent: WO 98/29439 (1998-07-01), None
patent: WO 98/34948 (1998-08-01), None
patent: WO 98/38217 (1998-09-01), None
patent: WO 98/46620 (1998-10-01), None
patent: WO 98/46995 (1998-10-01), None
patent: WO 98/56820 (1998-12-01), None
patent: WO 99/06552 (1999-02-01), None
patent: WO/99 24569 (1999-05-01), None
patent: WO 99/32519 (1999-07-01), None
patent: WO 99/48921 (1999-09-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/14229 (2000-03-01), None
patent: WO 00/22131 (2000-04-01), None
patent: WO 00/49046 (2000-08-01), None
patent: WO 01/07606 (2001-02-01), None
patent: WO 01/09184 (2001-02-01), None
patent: WO 01/12673 (2001-02-01), None
patent: WO 01/14577 (2001-03-01), None
patent: WO 01/16159 (2001-03-01), None
patent: WO 01/31014 (2001-05-01), None
patent: WO 01/36471 (2001-05-01), None
Bao, et al., Database SwissProt. Acc. No. P25089, May 1, 1992, Alignment for SEQ ID No. 2.
Bao, et al, Database PIR 73, Acc. No. C42009, Sep. 30, 1993, Alignment for SEQ ID No. 3.
Durstin, et al., EMBL Database, Acc No. AC005946, Nov. 8, 1994, Alignment for SEQ ID No. 1.
Lamerdin, et al., EMBL Database, Acc. No. AC005946, Nov. 7, 1998, Alignment for SEQ ID No. 1.
Lamerdin, et al., EMBL Database, Acc No. AC06272, Jan. 4, 1999, Alignment for SEQ ID No. 1.
Alla, S.A. et al., “Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies,”J. Biol. Chem., 1996, 271, 1748-1755.
Advenier, C. et al., “Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK2) receptors,”Am. Rev. Respir. Dis., 1992, 146(5, Pt. 1), 1177-1181.
Alexander, W.S. et al., “Point mutations within the dimer interfact homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity,”EMBO J., 1995, 14(22), 5569-5578.
Arvanitikis, L. et al., “Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation,”Nature, 1997, 385, 347-349.
Barker, E.L. et al., “Constitutively active 5-hydroxytryptamine2Creceptors reveal novel inverse agonist activity of receptor ligands,”J. Biol. Chem., 1994, 269(16), 11687-11690.
Baxter, G., “5-HT2receptors: a family re-united?”Trends Pharmacol. Sci., 1995, 16, 105-110.
Besmer, P. et al., “A new acute transforming feline retrovirus and relationship of its oncogene v-kitwith the protein kinase gene family,”Nature, 1986, 320, 415.
Blin, et al., “Mapping of single amino acid residues required for selective activation of Gq/11by the m3 muscarinic acetylcholine receptor,”J. Biol. Chem., 1995, 270, 17741-17748.
Bond, R.A. et al., “Inverse agonists and G-protein-coupled receptors,” inReceptor-Based Drug Design, Leff, P. (ed.), New York, M. Dekker, 1998, 363-377.
Boone, C. et al., “Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype,”Proc. Natl. Acad. Sci. USA, 1993, 90(21), 9921-9925.
Burstein, E.S. et al., “Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains,”Biochem. Pharmacol., 1996, 51(4), 539-544.
Burstein, E.S. et al., “Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop,”J. Biol. Chem., 1996, 271(6), 2882-2885.
Burstein, E.S. et al., “Constitutive activation of muscarinic receptors by the G-protein Gq,”FEBS Lett., 1995, 363(3), 261-263.
Bylund, D., “International union of pharmacology nomenclature of adrenoceptors,”Pharmacol. Rev., 1994, 46, 121-136.
Casey, C. et al., “Constitutively active mutant 5-HT2Aserotinin receptors: inverse agonist activity of classical 5HT2Aantagonists,”Soc. Neurosci., 1996, Abstract #699.10.
Cheatham, B. et al., “Substitution of theerbB-2oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin-receptor substrate 1,”Proc. Natl. Acad. Sci. USA, 1993, 90, 7336-7340.
Chen, J. et al., “Tethered Ligand Library for Discovery of Peptide Agonists,”J. Biol. Chem., 1995, 270, 23398-23401.
Chen, T.S. et al., “Microbiol hydroxylation and glucuronidation of the angiotensin II (AII) receptor antagonist MK 954,”J. Antibiot. (Tokyo), 1993, 46(1), 131-134.
Chen, W. et al., “A colorimetric assay for measuring activation of Gs- and Gq-coupled signaling pathways,”Anal. Biochem., 1995, 226(2), 349-354.
Chidiac, P. et al., “Inverse agonist activity of β-adrenergic antagonists,”J. Pharm. Exp. Ther., 1994, 45, 490-499.
Clozel, M. et al., “In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology,”J. Cardiovas. Pharmacol., 1993, 22(Suppl. 8), S377-S-379.
Collesi, C. et al., “A splicing variant of theRONtranscript induces constitutive tyrosine kinase activity and an invasive phenotype,”Mol. Cell. Biol., 1996, 16(2), 5518-5526.
Cooper, C.S. et al., “Molecular cloning of a new transforming gene from a chemically transformed human cell line,”Nature, 1984, 311, 29-33.
De Dios, I. et al., “Effect of L-364,718 (CCK Receptor Antagonist) on Exocrine Pancreatic Secretion of Hydrocortison-Treated Rats,”Pancreas, 1994, 9(2), 212-218.
Desbios-Mouthon, C. et al., “Deletion of Asn281in the α-subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization,”J. Clin. Endocrinol. Metab., 1996, 81(2), 719-727.
Di Renzo, M.F. et al., “Expression of the Met/HGF receptor in normal and neoplastic human tissues,”Oncogene, 1991, 6(11), 1997-2003.
Di Renzo, M.F. et al., “Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas,”Oncogene, 1992, 7, 2549-2553.
Duprez, L. et al., “Germline mutations of the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperethyroidism,”Nature Genetics, 1994, 7, 396-401.
Eggericksx, D. et al., “Molecular Cloning of an Orphan G-Protein-Coupled Receptor that Constitutively Activates Adenylate Cyclase,”Biochem. J., 1995, 309, 837-843.
Evans, B.E. et al., “Orally Active, Nonpeptide Oxytocin Antagonists,”J. Med. Chem., 1992, 35, 3919-3927.
Fu, M. et al., “Functional autoimmune epitope on α1-adrenergic receptors in patients with malignant hypertension,”Lancet, 1994, 344, 1660-1663.
Furitsu, T. et al., “Identification of Mutations in the Coding Sequence of the Proto-oncogene c-kitin a Human Mast Cell Leukemia Cell Line Causing Ligand-independent Activation of c-kitProduct,”J. Clin. Invest., 1993, 92, 1736-1744.
G
Behan Dominic P.
Chalmers Derek T.
Leonard James N.
Liaw Chen W.
Lin I-Lin
Andres Janet L.
Arena Pharmaceuticals Inc.
Basi Nirmal S.
O'Connor Cozen
Patané Michael A.
LandOfFree
Endogenous and non-endogenous versions of human G... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Endogenous and non-endogenous versions of human G..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endogenous and non-endogenous versions of human G... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711786